SCHEMBL5459978

SCHEMBL5459978

CC(C)C1=NN(c2cc(Cl)cc(Cl)c2)C(=O)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
KMT2A Q03164 5/20 0.45
KDM4E B2RXH2 5/20 0.45
GAA P10253 3/20 0.45
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 4/20 0.45
TDP1 Q9NUW8 3/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
TSHR P16473 2/20 0.38
POLB P06746 2/20 0.37
CASP6 P55212 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CYP1A2 P05177 1/20 0.37
CHRM2 P08172 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455119 0.81 KDM4E (0.48) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL5457558 0.81 KMT2A (0.45) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL5455129 0.79 KMT2A (0.54) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL5976227 0.78 GAA (0.62) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL5462610 0.77 MAPT (0.72) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL5781892 0.77 MAPT (0.43) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL5464226 0.77 MAPT (0.43) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL5468382 0.75 MAPT (0.51) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL10889560 0.74 MAPT (0.51) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL5465636 0.73 LOX (0.64) MAPTKMT2AKDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 MAPT 4163/4885KMT2A 2948/4885KDM4E 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.